复星医药(02196.HK)子企小细胞肺癌药物一线治疗上市许可获欧盟批准

阿斯达克财经
06 Feb

复星医药(02196.HK) 公布,其控股子公司复宏汉自主研发的斯鲁利单抗注射液(即抗 PD-1单抗,欧盟商品名:Hetronifly)联合卡铂和依托泊苷适用于广泛期小细胞肺癌(ES-SCLC)成人患者的一线治疗的上市许可申请(MAA),于近日获欧盟委员会(即European Commission)批准。

据此,该药品获得所有欧盟成员国及冰岛、列支敦士登和挪威的集中上市许可,并成为首个欧盟批准用于广泛期小细胞肺癌(ES-SCLC)治疗的抗PD-1单抗。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10